Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Insmed Incorporated stock logo
INSM
Insmed
$98.73
+1.9%
$71.41
$60.40
$100.00
$17.98B0.82.16 million shs5.32 million shs
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$34.84
-1.2%
$32.82
$24.05
$35.38
$19.59B0.483.61 million shs3.52 million shs
Shiseido Company, Limited stock logo
SSDOY
Shiseido
$16.89
-1.5%
$16.38
$15.32
$32.20
$6.75B0.3395,492 shs25,928 shs
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$17.00
-4.0%
$16.04
$12.47
$22.80
$19.49B0.610.19 million shs13.36 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Insmed Incorporated stock logo
INSM
Insmed
0.00%+34.11%+46.88%+28.97%+60.15%
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
0.00%+3.14%+5.19%+6.32%+28.09%
Shiseido Company, Limited stock logo
SSDOY
Shiseido
0.00%+2.54%+2.54%-12.53%-47.71%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.00%-4.30%+0.99%+3.80%-1.27%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Insmed Incorporated stock logo
INSM
Insmed
3.2931 of 5 stars
2.51.00.04.32.71.70.6
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
4.721 of 5 stars
3.61.03.33.73.41.71.9
Shiseido Company, Limited stock logo
SSDOY
Shiseido
2.3724 of 5 stars
0.05.00.80.03.00.01.9
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
3.9977 of 5 stars
4.65.00.80.02.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Insmed Incorporated stock logo
INSM
Insmed
3.00
Buy$104.816.16% Upside
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
3.25
Buy$47.3335.86% Upside
Shiseido Company, Limited stock logo
SSDOY
Shiseido
0.00
N/AN/AN/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
3.20
Buy$24.4443.82% Upside

Current Analyst Ratings Breakdown

Latest SSDOY, TEVA, RPRX, and INSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Insmed Incorporated stock logo
INSM
Insmed
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $112.00
6/11/2025
Insmed Incorporated stock logo
INSM
Insmed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
6/11/2025
Insmed Incorporated stock logo
INSM
Insmed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.00
6/11/2025
Insmed Incorporated stock logo
INSM
Insmed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.00
6/11/2025
Insmed Incorporated stock logo
INSM
Insmed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$107.00 ➝ $119.00
6/11/2025
Insmed Incorporated stock logo
INSM
Insmed
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$94.00 ➝ $109.00
6/11/2025
Insmed Incorporated stock logo
INSM
Insmed
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$90.00 ➝ $120.00
6/10/2025
Insmed Incorporated stock logo
INSM
Insmed
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/10/2025
Insmed Incorporated stock logo
INSM
Insmed
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy
6/10/2025
Insmed Incorporated stock logo
INSM
Insmed
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$100.00 ➝ $115.00
6/6/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$24.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Insmed Incorporated stock logo
INSM
Insmed
$381.03M47.19N/AN/A($2.32) per share-42.56
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$2.26B8.65$4.39 per share7.94$17.94 per share1.94
Shiseido Company, Limited stock logo
SSDOY
Shiseido
$6.55B1.03$1.63 per share10.34$11.31 per share1.49
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$16.62B1.17$3.37 per share5.05$4.75 per share3.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Insmed Incorporated stock logo
INSM
Insmed
-$749.57M-$5.95N/AN/AN/A-251.24%-4,773.73%-54.58%8/6/2025 (Estimated)
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$858.98M$1.8524.037.172.3137.94%24.40%14.01%8/6/2025 (Estimated)
Shiseido Company, Limited stock logo
SSDOY
Shiseido
-$71.52M-$0.07N/A20.35N/A-1.10%-1.68%-0.82%8/6/2025 (Estimated)
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$1.15N/A6.461.44-9.91%42.46%6.65%7/30/2025 (Estimated)

Latest SSDOY, TEVA, RPRX, and INSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Shiseido Company, Limited stock logo
SSDOY
Shiseido
$0.0569$0.06+$0.0031$0.06$1.72 billion$1.54 billion
5/8/2025Q1 2025
Insmed Incorporated stock logo
INSM
Insmed
-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million
5/8/2025Q1 2025
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$0.99$1.06+$0.07$0.41$724.69 million$839.00 million
5/7/2025Q1 2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.47$0.52+$0.05$0.18$3.99 billion$3.89 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Insmed Incorporated stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$0.882.53%N/A47.57%5 Years
Shiseido Company, Limited stock logo
SSDOY
Shiseido
$0.070.41%N/AN/A N/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$1.015.95%N/AN/A N/A

Latest SSDOY, TEVA, RPRX, and INSM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/21/2025
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
quarterly$0.222.7%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Insmed Incorporated stock logo
INSM
Insmed
2.03
6.37
5.99
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
0.64
1.44
1.44
Shiseido Company, Limited stock logo
SSDOY
Shiseido
0.30
1.08
0.68
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.97
0.98
0.75

Institutional Ownership

CompanyInstitutional Ownership
Insmed Incorporated stock logo
INSM
Insmed
N/A
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
54.35%
Shiseido Company, Limited stock logo
SSDOY
Shiseido
0.02%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
Insmed Incorporated stock logo
INSM
Insmed
3.00%
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
18.90%
Shiseido Company, Limited stock logo
SSDOY
Shiseido
N/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
Insmed Incorporated stock logo
INSM
Insmed
373182.14 million170.67 millionOptionable
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
80562.24 million477.83 millionOptionable
Shiseido Company, Limited stock logo
SSDOY
Shiseido
30,540399.66 millionN/ANot Optionable
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
36,8001.15 billion1.13 billionOptionable

Recent News About These Companies

Americares, HDA honor Teva with Power of Partnership Award

New MarketBeat Followers Over Time

Media Sentiment Over Time

Insmed stock logo

Insmed NASDAQ:INSM

$98.73 +1.85 (+1.91%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$98.62 -0.11 (-0.11%)
As of 06/13/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Royalty Pharma stock logo

Royalty Pharma NASDAQ:RPRX

$34.84 -0.43 (-1.22%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$34.66 -0.18 (-0.50%)
As of 06/13/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Shiseido stock logo

Shiseido OTCMKTS:SSDOY

$16.89 -0.27 (-1.54%)
As of 06/13/2025 03:59 PM Eastern

Shiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; and skincare and makeup products. It also engages in the restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. Further, it offers childcare facilities. The company sells its products through department, specialized cosmetic, drug, and general merchandise stores. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$17.00 -0.71 (-4.03%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$17.07 +0.07 (+0.40%)
As of 06/13/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.